

Info Sheet for Technical description

No. 0015

Organization

* Mandatory fields

Name of Organization*	VCCT Inc.	
Address, City, States, Zip, Country*	Kobe Eye Center 5F, 2-1-8 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047 Japan	
URL	https://www.vcct.jp/en/	
Brief Descriptions of Organization* (Approx. 100 words)	VCCT Inc. is dedicated to the development and application of advanced cell therapy for patients suffering from retinal degeneration diseases including Retinitis Pigmentosa (RP) and age-related macular degeneration (AMD). Backed by the robust preclinical data and leveraging the close relationship with Kobe City Eye Hospital, our cell therapies have been applied to 10 patients with AMD and RP across multiple investigator-initiated trials, in which the safety was observed and some patients showed reversal of vision deterioration. VCCT is now actively working on developing allogeneic iPSC-derived RPE strip and allogeneic iPSC-derived photoreceptor organoid utilizing the gene editing technology for the enhancement of safety and efficacy.	
Contact address	Name*	Akio Narukawa
	Department* / Position	Business Development / Director
	E-mail* / TEL	bd@vcct.jp

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines → Please see **Sheet [A]**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☒ Yes
- ☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☒ Series A
- ☐ Series B
- ☐ Series C
- ☐ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☐ Yes	
☒ No	Please contact us directly

Filled in by*

Date*

Akio Narukawa
9/3/25

Sheet [A] Clinical Development Pipelines**Info Sheet for Technical overview**

No. A-0015

* Mandatoty fields

Title***Pipeline of VCCT****Development Phase***

- | | | |
|--|--|---|
| ☐ Basic Research | ☐ Drug Discovery | ☒ Pre-Clinical |
| ☒ Clinical Trial (Phase I) | ☐ Clinical Trial (Phase II) | ☐ Clinical Trial (Phase III) |
| ☐ Review | ☐ Others | |

Diesease Area*

- | | | |
|--|---|---|
| ☐ Cancer | ☐ Central nervous system | ☒ Ophthalmology |
| ☐ Musculoskeletal | ☐ Endocrine / Metabolism | ☐ Cardiovascular |
| ☐ Urogenital | ☐ Digestive organ | ☐ Blood |
| ☐ Infection | ☐ Dermatology | ☐ Immunity |
| ☐ Otolaryngology | ☐ Respiratory | ☐ Others |

Description***【MastCT-01】** Allogeneic iPSC-derived RPE

Targets: Retinal degeneration diseases with RPE degeneration

Donor iPSC-derived retinal pigment epithelial cells. RPE cells are prepared in a "strip" formulation, which enables targeted delivery into retinal lesion and prevent formation of epi-retinal membrane.

【MastCT-03】 Allogeneic gene-edited iPSC-derived RPE cells

Targets: Retinal degeneration diseases with RPE degeneration

Donor HLA-KO iPSC-derived retinal pigment epithelial cells. RPE cells are prepared in a "strip" formulation, which enables targeted delivery into retinal lesion and prevent formation of epi-retinal membrane. Additionally, they are hypo-immunogenic – experiments in monkeys showed that the cells integrate into host without any immuno-suppression. Manufactured using automated robots.

【MastCT-PR】 Allogeneic iPSC-derived retinal organoids

Targets: Retinitis Pigmentosa, AMD and others

Donor iPSC-derived photoreceptor organoids at pre-clinical stage. It is preapred as a polarized sheet of ~1cm diameter, highly reminiscent to human retina. Animal studies showed that, once transplanted, the organoids can form synapses and improve visual acuity of otherwise blind mice. The organoids are manufactured using automated robots and delivered into sub-retinal space using standard needle/syringes.

<https://www.vcct.jp/en/pipeline-en/>**Filled in by***

Akio Narukawa

Date*

9/3/25